GSK: Result Summaries: Compounds > fondaparinux sodium

Home > Result Summaries: Compounds > fondaparinux sodium

Result Summaries: fondaparinux sodium

Result Summaries for fondaparinux sodium
GSK Study ID	Phase	Title
095-002	Phase 3	A multicenter, multinational, randomized, double-blind comparison of subcutaneous Org31540/SR90107A with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective major knee surgery or a revision (PENTAMAKS). (1 citation(s))
103413	Phase 3	An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Sodium Versus Control Therapy in a Broad Range Of Subjects With ST Segment Elevation Acute Myocardial Infarction. (1 citation(s))
103414	Phase 3	A multicenter, randomized, double-blind, parallel group trial to demonstrate the efficacy of fondaparinux sodium in association with Intermittent Pneumatic Compression versus Intermittent Pneumatic Compression used alone for the prevention of venous thromboembolic events in subjects at increased ... (0 citation(s))
103420	Phase 3	An International, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Fondaparinux versus Enoxaparin in the Acute Treatment of Unstable Angina /Non ST-Segment Elevation MI Acute Coronary Syndromes (2 citation(s))
104326	Phase 4	ARISTOTE Study: French cohort Study conducted to determine how ARIXTRA® 2.5 mg is used in every day practice, and to document the incidence of Venous Thromboembolic Events (VTEs) and major bleeding after orthopaedic surgery (0 citation(s))
104574	Phase 2	A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) (1 citation(s))
104619	Phase 3	A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). (9 citation(s))
106206	phase 3	Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE) (0 citation(s))
108034	Phase 4	A post marketing survailance to monitor the safety of Arixtra administered in Korean subjects according to the prescription information (0 citation(s))
110147	Phase 4	ARIANE study: Arixtra and Platelet Monitoring (0 citation(s))
111271	Phase 4	Arixtra observational study; A multi-centre, prospective observational study to evaluate the incidence of venous thromboembolism(VTE) in Korean patients with Arixtra™ therapy in real world setting (0 citation(s))
111436	phase 3	Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT) (0 citation(s))
63109_B	Phase 1	Interaction study with Org31540/SR90107A and piroxicam in healthy male volunteers (4 citation(s))
ACT1840	Phase 2	A multicentre pilot study of natural pentasaccharide (SR90107A /Org31540) for the prevention of deep venous thrombosis after total hip replacement. (0 citation(s))
ACT2445	Phase 2	Pilot efficacy study of a single I.V. injection of Pentasaccharide (SR90107A/ORG 31540) in patients undergoing coronary angioplasty (2 citation(s))
ACT2545	Phase 2	A multicentre dose finding study of once daily injection of Natural Pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. (1 citation(s))
AR3106116	Phase 3	Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) after Abdominal Surgery (0 citation(s))
AR3106333	Phase 3	Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism after Elective Total Hip Replacement Surgery (0 citation(s))
AR3106335	Phase 3	Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism after Hip Fracture Surgery (0 citation(s))
ART108053	phase 3	See Detailed Description (0 citation(s))
BDR3780	Phase 1	A single dose bioequivalence study comparing a new formulation of Org31540/SR90107A and the reference formulation in healthy male subjects (4 citation(s))
BDR4979	Phase 1	A single dose bioequivalence study comparing a new formulation of fondaparinux sodium at 12.5 mg/mL and the reference formulation at 10 mg/mL, in healthy male subjects. Open, randomized, crossover and single center study (0 citation(s))
C8843	Phase 3	Multinational/multicentre, non-randomized, open label study to assess efficacy and safety of fondaparinux sodium (ARIXTRA.) use in daily practice in subjects undergoing major orthopedic surgery of the lower limbs (0 citation(s))
DRI2643	Phase 2	A multicenter, randomized, parallel, double-blind, dose ranging study of subcutaneous Org31540/SR90107A with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement (Pentathlon). (1 citation(s))
DRI3196	Phase 2	A multicentre, randomised, dose-ranging study comparing Org31540/SR90107A with heparin as adjunctive therapy to recombinant tissue plasminogen activator and Aspirin in acute myocardial infarction (AMI) (PENTALYSE) (2 citation(s))
DRI4090	Phase 3	A multicenter, randomized, double-blind, placebo controlled, parallel group, dose response study of subcutaneous Org31540/SR90107A in the prevention of venous thromboembolism after elective total hip replacement surgery. (0 citation(s))
DRI4757	Phase 3	A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose response study of subcutaneous Org31540/SR90107A in the prevention of venous thromboembolism after elective total knee replacement surgery. (0 citation(s))
EFC2441	Phase 3	A multicentre, randomized, double-blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE-DVT) (9 citation(s))
EFC2442	Phase 3	A multicenter, multinational, randomized, double-blind comparison of subcutaneous Org31540/SR90107A with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective hip replacement or a revision. PENTATHLON 2000 (1 citation(s))
EFC2698	Phase 3	A multicenter, multinational, randomized double-blind comparison study of subcutaneous Org31540/SR90107A versus enoxaparin 40 mg o.d. in the prevention of deep vein thrombosis and symptomatic pulmonary embolism in hip fracture surgery. (PENTHIFRA) (6 citation(s))
EFC3557	Phase 3	A multicenter, multinational, randomized, double-blind study to compare the efficacy and safety of fondaparinux sodium (Org31540/SR90107A) with dalteparin (Fragmin) in the prevention of venous thromboembolic events in high-risk abdominal surgery (PEGASUS) (6 citation(s))
EFC4582	Phase 3	A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS) (21 citation(s))
INT 2767	Phase 1	Interaction Study of 975mg Aspirin Given at Steady State of 10mg/sc SR90107A/Org31540 in Healthy Male Subjects (3 citation(s))
INT 3012	Phase 2	Influence of Forced Diuresis on the Pharmacokinetics of Org31540/SR90107 After a Single Dose of 10 mg s.c. of Org31540/SR90107A in Healthy Male Subjects (1 citation(s))
INT3933	Phase 1	Assessment of pharmacokinetic and pharmacodynamic drug interactions between ORG31540/SR90107A and digoxin in healthy male subjects (3 citation(s))
L_8598	Phase 4	Fondaparinux sodium in ORthopaedic SurgEry (FORSE): A Prospective Evaluation of ArixtraTM for the Prevention of Symptomatic Venous Thromboembolism in Orthopaedic Surgery (0 citation(s))
L8405	Phase 3	A multi-centre, randomised, open-label, parallel group, comparative study of the efficacy and safety of once daily fondaparinux 2.5mg versus fondaparinux 2.5mg plus graduated compression stockings for the prevention of venous thromboembolism in patients undergoing elective or emergency hip surgery (0 citation(s))
L8518	Phase 4	Flexibility in administration of Arixtra for prevention of symptomatic venous thromboembolism in orthopedic surgery (4 citation(s))
L-8541	Phase 3	Arixtra VTE Prevention Study - Fondaparinux compared with enoxaparin in the prevention of venous thromboembolism (VTE) in Chinese patients undergoing elective knee replacement, hip surgery or a revision of components. (0 citation(s))
L-8635	Phase 3	Fondaparinux compared with enoxaparin in the prevention of venous thromboembolism in Taiwanese patients undergoing elective knee replacement. (0 citation(s))
P1653	Phase 1	A single rising dose study of the safety, tolerability, pharmacokinetics & pharmacodynamics of subcutaneous SR90107A/ORG31540 natural pentasaccaride in healthy male volunteers (1 citation(s))
PKM5053	Phase 1	A repeated dose study to assess the pharmacokinetic profiles and the safety of Org31540/SR90107A by subcutaneous administration of 0.75, 1.5, 2.5, and 3.0mg to Japanese healthy elderly subjects (0 citation(s))
POP5108	Phase 1	A repeated dose pharmacokinetic study in healthy volunteers to compare 1.5 mg of fondaparinux sodium in subjects with a low (35 to 50 kg) body weight (LBW) to 2.5 mg of fondaparinux sodium in subjects with standard (60 to 100 kg) body weight (SBW) (0 citation(s))
TDR3088	Phase 1	Safety, pharmacokinetics and pharmacodynamics (PD) of Org31540/SR90107A after repeated intravenous injection in healthy male volunteers (0 citation(s))
TDU3085	Phase 1	Safety and pharmacokinetics of ORG31540/SR90107A after a single intravenous injection in healthy male volunteers (0 citation(s))
TDU3166	Phase 1	A study to investigate the safety, pharmacokinetics and pharmacodynamics (PD) of ORG31540/SR90107A administered as a single intravenous drip to healthy male volunteers (0 citation(s))
TDU4089	Phase 1	A safety, pharmacokinetics and bioavailability study after single dose subcutaneous administration of Org31540/SR90107A 0.75, 2.5, and 8mg in young adult Japanese healthy male subjects. (0 citation(s))
TDU4289	Phase 1	A safety and pharmacokinetics study after single dose subcutaneous administration of Org31540/SR90107A 2.5mg in elderly Japanese healthy male volunteers. (0 citation(s))

Result Summaries: fondaparinux sodium

Filter list by: